Giredestrant
Small moleculeexperimental
Clinical trial activity
19 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
15
Phase 3
5
Phase 4
0
Earliest trial started Nov 27, 2017 (NCT03332797)
Timeline
Indications
Mechanism of action
- Estrogen receptorANTAGONIST
Estrogen receptor antagonist
- Estrogen receptor alphaDEGRADER
Estrogen receptor alpha degrader
Antagonises, leads to degradation
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@H]1Cc2c([nH]c3ccccc23)[C@@H](c2c(F)cc(NC3CN(CCCF)C3)cc2F)N1CC(F)(F)CO- Mol. weight
- 522.56 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650316 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07288359 | Phase 1/Phase 2 (Phase 2) | Mar 16, 2026 | Novartis |
| NCT07100106 | Phase 1/Phase 2 (Phase 2) | Oct 7, 2025 | Genentech, Roche |
| NCT06259929 | Phase 2 | Apr 1, 2024 | Fondazione Giovanni Pascale, Oncotech |
| NCT06065748 | Phase 3 | Dec 11, 2023 | Roche |
| NCT05896566 | Phase 2 | Dec 1, 2023 | ETOP IBCSG Partners Foundation, Roche |
| NCT05708235 | Phase 2 | Sep 30, 2023 | MedSIR, University of Valencia |
| NCT05659563 | Phase 2 | May 31, 2023 | MedSIR |
| NCT05634499 | Phase 2 | Jan 15, 2023 | Roche |
| NCT05306340 | Phase 3 | Aug 3, 2022 | Genentech |
| NCT05296798 | Phase 3 | Jul 4, 2022 | Roche |
| NCT04961996 | Phase 3 | Aug 27, 2021 | Roche |
| NCT04802759 | Phase 1/Phase 2 (Phase 2) | Jun 20, 2021 | Roche |
| NCT04680273 | Phase 1 | Jan 7, 2021 | Genentech |
| NCT04576455 | Phase 2 | Nov 27, 2020 | Roche |
| NCT04546009 | Phase 3 | Oct 9, 2020 | Roche |
| NCT04436744 | Phase 2 | Aug 31, 2020 | Roche |
| NCT04274075 | Phase 1 | Mar 6, 2020 | Genentech |
| NCT03916744 | Phase 1 | Jun 25, 2019 | Genentech, Roche |
| NCT03332797 | Phase 1 | Nov 27, 2017 | Genentech, Roche |
Showing 19 of 19 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 12 | 8 | 3 | 2017 |
| Genentech | For profit | 6 | 6 | 3 | 2017 |
| MedSIR | Academic/Hospital | 2 | 2 | 1 | 2023 |
| ETOP IBCSG Partners Foundation | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Fondazione Giovanni Pascale | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Novartis | For profit | 1 | 1 | 1 | 2026 |
| Oncotech | For profit | 1 | 1 | 1 | 2024 |
| University of Valencia | Academic/Hospital | 1 | 0 | 1 | 2023 |
8 organizations
Page 1 / 1